rs764070148
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_001365276.2(TNXB):βc.3290_3291delβ(p.Lys1097ArgfsTer48) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000168 in 1,608,920 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (β β ). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: π 0.000033 ( 0 hom., cov: 32)
Exomes π: 0.000015 ( 0 hom. )
Consequence
TNXB
NM_001365276.2 frameshift
NM_001365276.2 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 1.13
Genes affected
TNXB (HGNC:11976): (tenascin XB) This gene encodes a member of the tenascin family of extracellular matrix glycoproteins. The tenascins have anti-adhesive effects, as opposed to fibronectin which is adhesive. This protein is thought to function in matrix maturation during wound healing, and its deficiency has been associated with the connective tissue disorder Ehlers-Danlos syndrome. This gene localizes to the major histocompatibility complex (MHC) class III region on chromosome 6. It is one of four genes in this cluster which have been duplicated. The duplicated copy of this gene is incomplete and is a pseudogene which is transcribed but does not encode a protein. The structure of this gene is unusual in that it overlaps the CREBL1 and CYP21A2 genes at its 5' and 3' ends, respectively. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 16 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PP5
Variant 6-32084566-CTT-C is Pathogenic according to our data. Variant chr6-32084566-CTT-C is described in ClinVar as [Likely_pathogenic]. Clinvar id is 8550.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr6-32084566-CTT-C is described in Lovd as [Pathogenic]. Variant chr6-32084566-CTT-C is described in Lovd as [Pathogenic]. Variant chr6-32084566-CTT-C is described in Lovd as [Likely_pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TNXB | NM_001365276.2 | c.3290_3291del | p.Lys1097ArgfsTer48 | frameshift_variant | 8/44 | ENST00000644971.2 | NP_001352205.1 | |
TNXB | NM_019105.8 | c.3290_3291del | p.Lys1097ArgfsTer48 | frameshift_variant | 8/44 | NP_061978.6 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TNXB | ENST00000644971.2 | c.3290_3291del | p.Lys1097ArgfsTer48 | frameshift_variant | 8/44 | NM_001365276.2 | ENSP00000496448 | |||
TNXB | ENST00000375244.7 | c.3290_3291del | p.Lys1097ArgfsTer48 | frameshift_variant | 8/44 | 5 | ENSP00000364393 | |||
TNXB | ENST00000647633.1 | c.4031_4032del | p.Lys1344ArgfsTer48 | frameshift_variant | 9/45 | ENSP00000497649 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000329 AC: 5AN: 152194Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
5
AN:
152194
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000246 AC: 6AN: 244136Hom.: 0 AF XY: 0.0000150 AC XY: 2AN XY: 133606
GnomAD3 exomes
AF:
AC:
6
AN:
244136
Hom.:
AF XY:
AC XY:
2
AN XY:
133606
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000151 AC: 22AN: 1456726Hom.: 0 AF XY: 0.0000152 AC XY: 11AN XY: 724488
GnomAD4 exome
AF:
AC:
22
AN:
1456726
Hom.:
AF XY:
AC XY:
11
AN XY:
724488
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000329 AC: 5AN: 152194Hom.: 0 Cov.: 32 AF XY: 0.0000134 AC XY: 1AN XY: 74354
GnomAD4 genome
AF:
AC:
5
AN:
152194
Hom.:
Cov.:
32
AF XY:
AC XY:
1
AN XY:
74354
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Ehlers-Danlos syndrome due to tenascin-X deficiency Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Lifecell International Pvt. Ltd | - | A Heterozygous Frameshift variant c.3290_3291delAA in Exon 8 of the TNXB gene that results in the amino acid substitution p.Lys1097fs*48 was identified. The observed variant has a minor allele frequency of 0.00002/0.00010 in gnomAD exomes and genomes, respectively. The severity of the impact of this variant on the protein is high, based on the effect of the protein and REVEL score . Rare Exome Variant Ensemble Learner (REVEL) is an ensembl method for predicting the pathogenicity of missense variants based on a combination of scores from 13 individual tools: MutPred, FATHMM v2.3, VEST 3.0, PolyPhen-2, SIFT, PROVEAN, MutationAssessor, MutationTaster, LRT, GERP++, SiPhy, phyloP, and phastCons. The REVEL score for an individual missense variant can range from 0 to 1, with higher scores reflecting greater likelihood that the variant is disease-causing. ClinVar has also classified this variant as Likely Pathogenic [Variant ID: 8550]. This mutation has been detected as homozygous in two individuals from an Ehlers-Danlos syndrome (EDS) cohort (Schalkwijk J et al. 2001). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Jul 01, 2003 | - - |
TNXB-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Mar 13, 2024 | The TNXB c.3290_3291delAA variant is predicted to result in a frameshift and premature protein termination (p.Lys1097Argfs*48). This variant has been reported to be pathogenic for autosomal recessive classical-like Ehlers-Danlos syndrome (EDS) (Fig. 4C of Schalkwijk et al. 2001. PubMed ID: 11642233). Of note, this variant has also been associated with hypermobility type EDS due to TNXB haploinsufficiency (reported as "[AA56063] del" in Zweers et al. 2003. PubMed ID: 12865992). This variant is reported in 0.0064% of alleles in individuals of European (Non-Finnish) descent in gnomAD. Frameshift variants in TNXB are expected to be pathogenic. This variant is interpreted as pathogenic. - |
not provided Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Mar 30, 2022 | In a Letter to the Editor from the authors of Schalkwijk et al. (2001), the group reports additional workup on the family members of their previous cohort; authors observed that heterozygous family members were found to have significantly reduced tenascin X levels with a female-skewed preponderance for joint hypermobility (Zweers et al., 2003); Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 26582918, 11642233, 12865992) - |
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 10, 2019 | The c.3290_3291delAA pathogenic mutation, located in coding exon 7 of the TNXB gene, results from a deletion of two nucleotides at nucleotide positions 3290 to 3291, causing a translational frameshift with a predicted alternate stop codon (p.K1097Rfs*48). This mutation has been detected as homozygous in two individuals from an Ehlers-Danlos syndrome (EDS) cohort (Schalkwijk J et al. N. Engl. J. Med., 2001 Oct;345:1167-75). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at